Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Share Option Schemes

15 Feb 2012 07:00

RNS Number : 4324X
Imaginatik PLC
15 February 2012
 



15 February 2012

Imaginatik plc

("Imaginatik" or the "Company")

 

Share Option Schemes

 

Imaginatik plc (AIM: IMTK), a leading provider of enterprise innovation services including a range of technology products and consultancy, announces that the remuneration committee of the Board has approved changes to the terms of the existing share options issued by the Company.

 

There are currently 27,461,845 options outstanding under the Company's various share option schemes, of which 24,012,500 are held by directors and eligible employees. 12,006,250 of these options have now been cancelled and the exercise price of a further 12,006,250 options, which currently ranges from 2.0p to 2.55p, has been rebased to 1p per share. The mid-market price of the Company's ordinary shares as at close of business on 14 February 2012 was 0.42p.

 

In addition, the Company has awarded 64,425,000 new share options to directors and employees with an exercise price of 1p per share ("New Options"):

 

a. Matt Cooper, Shawn Taylor, Luis Solis and Nicholas Goss, each being an executive director of the Company, have been granted 17,500,000, 11,125,000, 7,500,000 and 5,000,000 options respectively. The grant of a higher number of options to Mr Cooper and Mr Taylor is in recognition of salary sacrifices on their part during the half-year to 30 September 2011. The share options for Mr Cooper and Mr Taylor will be a combination of options issued under The Imaginatik plc Enterprise Management Incentive Scheme ("EMI scheme") as well as unapproved options. The share options for Mr Goss will all be issued under the EMI scheme. The share options for Mr Solis shall be issued under the Imaginatik 2006 Stock Option Plan.

 

b. David Gammon, Simon Charles and Brian Hays, non-executive directors of the Company, have each been granted 2,000,000 share options. The share options for Mr Gammon and Mr Charles shall be issued as unapproved options, and those for Mr Hays shall be issued under the Imaginatik 2006 Stock Option Plan.

 

c. Key employees of the Company have been granted 17,300,000 share options under the EMI scheme as well as the Imaginatik 2006 Stock Option Plan.

 

The re-based options and the New Options will vest as to 50% two years after grant and 50% three years after grant, subject to certain events as particularised in the scheme rules.

 

The remuneration committee considers that the grant of the New Options and the combined re-basing and cancellation of existing options provides the senior management team and employees of the Company with an appropriate and effective incentive for the future.

 

In addition to the above grants, Northland Capital Partners Limited has been granted 3,206,451 options over new ordinary shares exercisable at any time at 0.5p per share expiring on 13 February 2017 (in connection with the recent placing and open offer).

 

Imaginatik now has 78,087,046 share options in issue, representing approximately 15.22% of the current issued share capital and 13.21% of the fully diluted share capital.

 

Executive Directors

Options

Matt Cooper

19,062,500

Shawn Taylor

14,225,000

Luis Solis

9,500,000

Nicholas Goss

5,000,000

Non-Executive Directors

David Gammon

2,000,000

Simon Charles

2,000,000

Brian Hays

2,000,000

Employees

17,643,750

Ex-employees

3,449,345

Northland Capital Partners

3,206,451

 

 

 

Matt Cooper, Shawn Taylor and Luis Solis, Executive Directors of the Company and Mr Andrew Wainwright, a former Executive Director of the Company, are participating in the re-basing of the existing share options to the extent of an aggregate of 8,537,500 options. The re-basing of the share options is deemed to be a related party transaction under the AIM Rules for Companies. Nicholas Goss, Brian Hays and David Gammon, the independent directors of the Company for the purposes of the transaction, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, consider that the terms of the re-basing of the existing share options are fair and reasonable so far as the shareholders of the Company are concerned.

 

Matt Cooper, Executive Chairman of Imaginatik, commented, "Following a comprehensive review of the Company's share option schemes, we are pleased to have put in place a revised share option structure that we believe properly incentivises our employees to build the Company in the long term."

 

For further information please contact:

 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

 

About Imaginatik

 

Imaginatik provides Innovation and Idea management solutions comprised of consultancy, software and program management to deliver innovation outcomes to companies such as The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. This is Imaginatik's area of expertise.

 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and a World Economic Forum Technology Pioneer with offices in Boston, MA, and London. In 2009, Imaginatik was named as one of the 500 fastest growing technology companies in the EMEA region by Deloitte. For more information, visit www.imaginatik.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFVTFRISLIF
Date   Source Headline
25th Jan 201211:30 amRNSHolding(s) in Company
23rd Jan 20127:01 amRNSContract Renewals worth £1.1m
3rd Jan 20127:00 amRNSDirectorate Change
22nd Dec 20117:00 amRNSContract extension
14th Dec 20117:00 amRNSLitigation Update
12th Dec 20117:00 amRNSContract Win
28th Nov 20117:00 amRNSHalf Yearly Report
28th Oct 20112:13 pmRNSChange of Adviser
28th Oct 201110:02 amRNSHolding(s) in Company
27th Oct 201110:45 amRNSHolding(s) in Company
13th Oct 20117:00 amRNSContract Extension
3rd Oct 201112:28 pmRNSDirectorate Change
26th Sep 20115:12 pmRNSResult of AGM
15th Sep 201110:24 amRNSHolding(s) in Company
2nd Sep 20113:25 pmRNSNotice of AGM
31st Aug 201111:46 amRNSHolding(s) in Company
26th Aug 20113:30 pmRNSResult of Open Offer and General Meeting
4th Aug 20119:32 amRNSPosting of Circular
2nd Aug 20117:15 amRNSProposed Placing, Subscription and Open Offer
2nd Aug 20117:00 amRNSFinal Results
29th Jul 201112:10 pmRNSNotice of Results
26th Apr 20117:00 amRNSIssue of Equity
14th Apr 20117:00 amRNSContract with the World Bank
1st Mar 20117:00 amRNSContract Wins and Trading Update
25th Jan 201111:22 amRNSWithdrawal of requisition of General Meeting
12th Jan 201111:01 amRNSHolding(s) in Company
11th Jan 20115:26 pmRNSIssue of Equity
22nd Dec 201012:24 pmRNSResult of General Meeting
22nd Dec 20107:00 amRNSFurther Requisition of General Meeting
16th Dec 20107:00 amRNSHalf Yearly Report
1st Dec 201010:08 amRNSNotice of General Meeting
19th Nov 20107:00 amRNSBoard Appointment
15th Nov 20103:28 pmRNSRequisition of General Meeting
11th Oct 20107:00 amRNSContract Extension with Pfizer
4th Oct 201011:58 amRNSShare Option Schemes
29th Sep 201011:41 amRNSResult of AGM
29th Sep 20107:00 amRNSAGM Statement
10th Sep 20105:00 pmRNSHolding in Company
10th Sep 20103:36 pmRNSHolding(s) in Company
10th Sep 20107:00 amRNSPilot Project Established with NASA
9th Sep 201012:47 pmRNSHolding(s) in Company
6th Sep 20104:14 pmRNSIssue of Equity
24th Aug 20103:16 pmRNSResult of General Meeting
18th Aug 20101:23 pmRNSMarket Update
6th Aug 20106:28 pmRNSPosting of Circular
30th Jul 20104:41 pmRNSHolding(s) in Company
27th Jul 20104:33 pmRNSPosting of Circular convening General Meeting
22nd Jul 201011:53 amRNSHolding(s) in Company
7th Jul 201011:04 amRNSSenior Management Team Appointments
23rd Jun 20107:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.